Director of Science
Labcorp Drug Development
Westampton, New Jersey
Mark Arnold, Ph.D. is Director of Science for Labcorp Drug Development. In that role, he collaboratively develops the bioanalytical scientific and regulatory strategy to meet current and future client needs for ligand-binding, PCR, cell-based and LC-MS/MS assays to quantify drugs and metabolites, antidrug antibodies and biomarkers in animal and clinical biological samples to support pharmacokinetic and pharmacodynamic assessments. Mark was previously Executive Director of the Bioanalytical Sciences Department of the Bristol-Myers Squibb Co. He received a B.S. in biology from Indiana University of Pennsylvania and Ph.D. in pharmacology from the University of Pittsburgh. For more than 35 years, Dr. Arnold has been involved in the field of bioanalysis, including the review and interpretation of regulations and guidance as they apply to the evolving field of bioanalysis. He was co-chair of both the AAPS Crystal City V and VI Workshops on the ‘FDA Draft Revised Guidance on Bioanalytical Method Validation’ and ‘Biomarkers’, respectively. He is actively involved the Land O’Lakes Bioanalytical Conference, American Association of Pharmaceutical Scientists (2022 RapidFire Committee Chair for PharmSci360 and was the 2021 Scientific Program Chair) and is an AAPS Fellow (2014). Dr. Arnold has over 100 peer-reviewed publications, 3 book chapters and numerous invited podium presentations.
Disclosure information not submitted.
Wednesday, October 19, 2022
9:30 AM – 10:00 AM ET
Wednesday, October 19, 2022
3:00 PM – 4:00 PM ET